Thursday, September 18, 2014 Last update: 7:33 PM - All Company Technology News Since 1996

Research and Markets: Global Squamous Cell Carcinoma Therapeutics Pipeline Review 2014

Companies mentioned in this article: Research and Markets

DUBLIN -- (BUSINESS WIRE) -- Research and Markets ( has announced the addition of the "Squamous Cell Carcinoma - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma and special features on late-stage and discontinued projects.


  • The report provides a snapshot of the global therapeutic landscape of Squamous Cell Carcinoma
  • The report reviews key pipeline products under the drug profile section, which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Squamous Cell Carcinoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Companies Involved in Therapeutics Development

  • Boehringer Ingelheim GmbH
  • Novartis AG
  • Genmab A/S
  • Celgene Corporation
  • Clinuvel Pharmaceuticals Limited
  • Oncolytics Biotech Inc.
  • Oryzon Genomics S.A.
  • Hutchison MediPharma Limited
  • Merrimack Pharmaceuticals, Inc.
  • Neotropix, Inc.
  • Axelar AB
  • Onconova Therapeutics, Inc.
  • Omeros Corporation
  • Cellceutix Corporation
  • Cannabis Science, Inc.
  • Oncovir, Inc.
  • Genextra S.p.A.
  • Bexion Pharmaceuticals, LLC
  • AbbVie Inc.

Drug Profiles

  • afatinib
  • paclitaxel albumin-bound
  • AXL-1717
  • pelareorep
  • rigosertib sodium
  • afamelanotide
  • boanmycin hydrochloride + [docetaxel]
  • CIGB-128
  • DAC-0060
  • Poly-ICLC
  • BYL-719
  • LJM-716
  • interleukin-15
  • Antibody Drug Conjugate for Squamous Cell Tumor
  • irinotecan sucrosofate liposomal
  • Kevetrin
  • CUV-9900
  • BXQ-350
  • CS-TATI-1
  • CS-S/BCC-1
  • TF-011-Monomethyl Auristatin E
  • AMXT-1501 + eflornithine
  • Allogenic Mesenchymal Stem Cells
  • HMPL-453
  • NTX-500
  • GPR87 Antagonist for Cancer
  • GPR39 Antagonist for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes
  • Monoclonal Antibody For Squamous Cell Cancer
  • Drugs for Cutaneous Squamous Cell Carcinoma (cSCC)

For more information visit

Copyright © Business Wire 2014

Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology